Cancer Advisor

Last revised: July 2026 .  Integrative Oncology · Protocol Review A comprehensive synthesis of Dr Makis's clinical dosing regimens, benzimidazole combination strategies, the 2026 Hulscher observational cohort, pharmacokinetic rationale, safety monitoring requirements, and anonymised patient outcome data — presented with evidence grading. OneDayMD Editorial Team  |  Medically reviewed and updated  |  About Us Abstract Background: Dr William Makis MD (McGill Medicine; 110+ peer-reviewed publications) has treated cancer patients using repurposed antiparasitic agents since 2023, publicly documenting protocols and outcomes via Substack and X (@MakisMD). His approach centres on high-dose ivermectin combined with benzimidazoles and metabolic interventions, customised by cancer type and stage. Purpose: This continuously updated review synthesises Dr Makis's published p...

I-PREVENT CANCER Protocol An Evidence-Based Guide to Cancer Prevention & Metabolic Optimization (2026 Edition) CRITICAL MEDICAL DISCLAIMER This protocol is an educational framework summarizing clinical and scientific literature regarding integrative oncology, metabolic optimization, and nutritional immunology. This content is intended strictly for cancer risk reduction and prevention . It is NOT a standalone cure, treatment, or substitute for conventional oncology care, surgery, radiation, or chemotherapy. Always consult your primary care physician or oncologist before modifying your healthcare or supplementation regimen. Table of Contents Introduction & The Modern Landscape Methodology & Evidence Quality Framework The Root Causes of Cancer: Epigenetics, Hallmarks & Metabolism Dietary Principles for Metaboli...

Multi-cancer early detection (MCED) tests are emerging as one of the most important developments in cancer screening. Instead of screening for one cancer at a time with mammography, colonoscopy, CT scans, or other conventional tests, MCED blood tests attempt to detect biological signals associated with multiple cancers from a single blood sample. Two of the most prominent commercial MCED tests in the United States are GRAIL's Galleri® test and Exact Sciences' Cancerguard® test . Both are designed to address a major problem in modern oncology: many cancers have no recommended routine screening test and may not be diagnosed until symptoms appear or the disease has progressed. But there is an important distinction between detecting a cancer signal and proving that a screening test saves lives . As MCED technology moves into a more important phase in 2026, the central question is no longer simply: Can a blood test detect cancer? The bigger question is: Can MCED scr...